These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36530229)

  • 1. Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules.
    Guerra Y; Celi D; Cueva P; Perez-Castillo Y; Giampieri F; Alvarez-Suarez JM; Tejera E
    ACS Omega; 2022 Dec; 7(49):44542-44555. PubMed ID: 36530229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS-COV-2 targeting main protease and papain-like protease.
    Choudhary S; Nehul S; Singh A; Panda PK; Kumar P; Sharma GK; Tomar S
    IUBMB Life; 2024 May; 76(5):228-241. PubMed ID: 38059400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2.
    Santos LH; Kronenberger T; Almeida RG; Silva EB; Rocha REO; Oliveira JC; Barreto LV; Skinner D; Fajtová P; Giardini MA; Woodworth B; Bardine C; Lourenço AL; Craik CS; Poso A; Podust LM; McKerrow JH; Siqueira-Neto JL; O'Donoghue AJ; da Silva Júnior EN; Ferreira RS
    bioRxiv; 2022 Jan; ():. PubMed ID: 35018373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.
    Tumskiy RS; Tumskaia AV; Klochkova IN; Richardson RJ
    Comput Biol Med; 2023 Feb; 153():106449. PubMed ID: 36586228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perceiving SARS-CoV-2 Mpro and PLpro dual inhibitors from pool of recognized antiviral compounds of endophytic microbes: an in silico simulation study.
    Prajapati J; Patel R; Rao P; Saraf M; Rawal R; Goswami D
    Struct Chem; 2022; 33(5):1619-1643. PubMed ID: 35431517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective inhibition of coronavirus replication by
    Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206
    [No Abstract]   [Full Text] [Related]  

  • 7.
    Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
    J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease.
    Liu W; Wang J; Wang S; Yue K; Hu Y; Liu X; Wang L; Wan S; Xu X
    Bioorg Chem; 2023 Nov; 140():106830. PubMed ID: 37683544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
    Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
    Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay.
    Narayanan A; Narwal M; Majowicz SA; Varricchio C; Toner SA; Ballatore C; Brancale A; Murakami KS; Jose J
    Commun Biol; 2022 Feb; 5(1):169. PubMed ID: 35217718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg
    Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS
    J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development.
    Lv Z; Cano KE; Jia L; Drag M; Huang TT; Olsen SK
    Front Chem; 2021; 9():819165. PubMed ID: 35186898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbial based natural compounds as potential inhibitors for SARS-CoV-2 Papain-like protease (PLpro): a molecular docking and dynamic simulation study.
    Rahul S; Sarkar A
    J Biomol Struct Dyn; 2022; 40(24):13848-13858. PubMed ID: 34730069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of natural compounds (proanthocyanidin and rhapontin) as high-affinity inhibitors of SARS-CoV-2 Mpro and PLpro using computational strategies.
    AlAjmi MF; Azhar A; Hasan S; Alshabr AZ; Hussain A; Rehman MT
    Arch Med Sci; 2024; 20(2):567-581. PubMed ID: 38757037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L.
    Meewan I; Kattoula J; Kattoula JY; Skinner D; Fajtová P; Giardini MA; Woodworth B; McKerrow JH; Lage de Siqueira-Neto J; O'Donoghue AJ; Abagyan R
    Pharmaceuticals (Basel); 2022 Jun; 15(6):. PubMed ID: 35745663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.
    Nogara PA; Omage FB; Bolzan GR; Delgado CP; Aschner M; Orian L; Teixeira Rocha JB
    Mol Inform; 2021 Aug; 40(8):e2100028. PubMed ID: 34018687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
    Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T
    Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions.
    Shawky AM; Almalki FA; Alzahrani HA; Abdalla AN; Youssif BGM; Ibrahim NA; Gamal M; El-Sherief HAM; Abdel-Fattah MM; Hefny AA; Abdelazeem AH; Gouda AM
    Eur J Med Chem; 2024 Nov; 277():116704. PubMed ID: 39121741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.
    Valipour M
    Eur J Med Chem; 2022 Oct; 240():114572. PubMed ID: 35797899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An automated positive selection screen in yeast provides support for boron-containing compounds as inhibitors of SARS-CoV-2 main protease.
    Sigurdardóttir S; Silva SF; Tiukova I; Alalam H; King RD; Grøtli M; Eriksson LA; Sunnerhagen P
    Microbiol Spectr; 2024 Oct; 12(10):e0124924. PubMed ID: 39162260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.